KR20250075621A - 항체 및 종양 저항에서의 이의 용도 - Google Patents

항체 및 종양 저항에서의 이의 용도 Download PDF

Info

Publication number
KR20250075621A
KR20250075621A KR1020257012739A KR20257012739A KR20250075621A KR 20250075621 A KR20250075621 A KR 20250075621A KR 1020257012739 A KR1020257012739 A KR 1020257012739A KR 20257012739 A KR20257012739 A KR 20257012739A KR 20250075621 A KR20250075621 A KR 20250075621A
Authority
KR
South Korea
Prior art keywords
cancer
antigen
antibody
seq
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257012739A
Other languages
English (en)
Korean (ko)
Inventor
이 루오
리안디 첸
웨이펑 황
샤오니우 먀오
야오 옌
차오 왕
Original Assignee
바이오세우스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오세우스 인크. filed Critical 바이오세우스 인크.
Publication of KR20250075621A publication Critical patent/KR20250075621A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G01N33/574—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hospice & Palliative Care (AREA)
KR1020257012739A 2022-09-20 2023-09-19 항체 및 종양 저항에서의 이의 용도 Pending KR20250075621A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202211142594 2022-09-20
CN202211142594.0 2022-09-20
PCT/CN2023/119761 WO2024061223A1 (zh) 2022-09-20 2023-09-19 抗体及其在抗肿瘤中的应用

Publications (1)

Publication Number Publication Date
KR20250075621A true KR20250075621A (ko) 2025-05-28

Family

ID=90453915

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257012739A Pending KR20250075621A (ko) 2022-09-20 2023-09-19 항체 및 종양 저항에서의 이의 용도

Country Status (5)

Country Link
EP (1) EP4592315A1 (https=)
JP (1) JP2025532665A (https=)
KR (1) KR20250075621A (https=)
CN (1) CN119894933A (https=)
WO (1) WO2024061223A1 (https=)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
JP2006500921A (ja) 2002-07-30 2006-01-12 ブリストル−マイヤーズ　スクイブ　カンパニー ヒト４−１ｂｂに対するヒト化抗体
CN102580084B (zh) * 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
JP6783797B2 (ja) 2015-05-04 2020-11-11 ピエリス ファーマシューティカルズ ゲーエムベーハー 抗がん融合ポリペプチド
KR102247704B1 (ko) * 2016-11-18 2021-05-03 북경한미약품 유한공사 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법
CN120383671A (zh) 2019-09-30 2025-07-29 阿迪马布有限责任公司 被工程化用于优先轻链配对的ch1结构域变体和包括所述ch1结构域变体的多特异性抗体
CN113004415B (zh) * 2019-12-19 2022-09-30 合肥瀚科迈博生物技术有限公司 靶向her2和4-1bb的双特异性抗体及其应用
CN114195900B (zh) * 2020-09-17 2024-02-23 普米斯生物技术(珠海)有限公司 一种抗4-1bb/pd-l1双特异性抗体及其用途
CN114195894B (zh) * 2020-09-17 2025-02-25 普米斯生物技术(珠海)有限公司 一种靶向4-1bb的抗体及其应用
JP2024534795A (ja) * 2021-08-18 2024-09-26 普米斯生物技術（珠海）有限公司 二重特異性抗体およびその使用

Also Published As

Publication number Publication date
WO2024061223A1 (zh) 2024-03-28
EP4592315A1 (en) 2025-07-30
JP2025532665A (ja) 2025-10-01
CN119894933A (zh) 2025-04-25

Similar Documents

Publication Publication Date Title
JP7058213B2 (ja) 改変ｊ鎖を有する結合分子
KR20220050971A (ko) 신규 항-cd39 항체
KR20210100654A (ko) Cd3 항체 및 그의 약제학적 용도
IL247715B (en) Antigen binding molecules that activate the immune system
EP2994490A1 (en) Bispecific constructs and their use in the treatment of various diseases
KR20200063153A (ko) Cd137을 표적화하는 항체 및 이의 사용 방법
TWI797609B (zh) 抗pd-1和pd-l1的四價雙特異性抗體
WO2022111576A1 (en) Novel conjugate molecules targeting cd39 and tgfβeta
WO2021003739A1 (zh) 四价对称双特异性抗体
JP7352007B2 (ja) ヒト化抗ｖｅｇｆモノクローナル抗体
KR20230028708A (ko) 항-b7-h4/항-4-1bb 이중특이적 항체 및 이의 용도
TW202208438A (zh) 抗ｌｉｌｒｂ１抗體或其抗原結合片段、製備其的方法、藥物組成物、核酸分子、重組載體以及重組細胞
CN110546164B (zh) 特异性结合cd40的抗体及其用途
KR20220030937A (ko) 항체 및 사용 방법
CN114829405B (zh) 抗bcma/抗4-1bb双特异性抗体及其用途
CN113307874B (zh) 一种抗lag3的抗体及其应用
WO2023030511A1 (en) Bi-functional fusion protein and uses thereof
CN112805068A (zh) 靶向cd137的抗体及其使用方法
EP4592315A1 (en) Antibody and use thereof in resisting tumor
EP4506361A1 (en) Antibody against c-met and use thereof
US20240317880A1 (en) Epithelial Cadherin-Specific Antibodies
CA3256233A1 (en) Antibody against c-met and use thereof
HK40078173B (zh) 抗bcma/抗4-1bb双特异性抗体及其用途
HK40078173A (en) Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
TW202204418A (zh) Ｐｄ－１抗原結合蛋白及其應用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000